{"id":"W1907039258","doi":"10.1111/apt.13408","title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","year":2015,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":173,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"UCB Pharma; Takeda Oncology; Tillotts Pharma; Genentech; Biogen; Celgene; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Wyeth Pharmaceuticals; Pfizer; ActoGeniX; Bristol-Myers Squibb","keywords":"Medicine; Ulcerative colitis; Mesalazine; Placebo; Internal medicine; Interim analysis; Clinical trial; Inflammatory bowel disease; Clinical endpoint; Interim; Endoscopy; Colonoscopy; Gastroenterology; Disease; Surgery; Pathology; Alternative medicine; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4627916,0.003263637,0.007095202,0.005555196,0.001132395,0.005415901,0.003075469,0.003169224,0.006943502],"category_scores_gemma":[0.5239714,0.001514281,0.01308241,0.006086703,0.002705328,0.004421435,0.003969524,0.006470215,0.001739055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002837623,"about_ca_system_score_gemma":0.005550578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002798535,"about_ca_topic_score_gemma":0.0003829467,"domain_scores_codex":[0.3373072,0.5593766,0.05711441,0.00856133,0.03597186,0.00166852],"domain_scores_gemma":[0.346226,0.4616888,0.1084982,0.03580932,0.04535963,0.002417967],"domain_codex":"methods","domain_gemma":"methods","domain_candidate":"methods","domain_consensus":"methods","study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1073627,0.003837771,0.08197141,0.05424866,0.06456147,0.0002163503,0.001561482,0.02443247,0.003335124,0.0276333,0.04391705,0.5869221],"study_design_scores_gemma":[0.1043101,0.1496732,0.2791702,0.02368592,0.04691446,0.001232821,0.001294547,0.08985534,0.01688362,0.06532456,0.2200368,0.001618488],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"methods","genre_scores_codex":[0.05343462,0.02987508,0.6743532,0.004557309,0.006200532,0.1827739,0.02510126,0.003130433,0.02057364],"genre_scores_gemma":[0.1410413,0.002927455,0.4079251,0.002131934,0.0008377714,0.4365312,0.007281131,0.0003656681,0.000958523],"genre_candidate":"methods","genre_consensus":"methods","teacher_disagreement_score":0.5372084,"threshold_uncertainty_score":0.6624737,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2507047214101915,"score_gpt":0.4853118432067941,"score_spread":0.2346071217966026,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}